Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.

Autor: Grut V; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden., Biström M; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden., Salzer J; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden., Stridh P; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Jons D; Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Gustafsson R; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Huang J; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Bergström T; Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Kockum I; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Waterboer T; Infections and Cancer Epidemiology Division, German Cancer Research Center, Heidelberg, Germany., Olsson T; Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.; Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden., Sundström P; Department of Clinical Science, Neurosciences, Umeå University, Umeå, Sweden.
Jazyk: angličtina
Zdroj: Annals of neurology [Ann Neurol] 2024 Aug; Vol. 96 (2), pp. 302-305. Date of Electronic Publication: 2024 Jun 11.
DOI: 10.1002/ana.27009
Abstrakt: Synergistic interactions between human herpesvirus 6A (HHV-6A) and Epstein-Barr virus (EBV) are hypothesized in the etiopathogenesis of multiple sclerosis (MS). This study investigated if HHV-6A and EBV seroreactivities interact regarding the risk of developing MS. Antibodies against viral antigens were analyzed in biobank samples from 670 individuals who later developed MS and matched controls. Additive interactions were analyzed. A significant interaction between HHV-6A and EBNA-1 seroreactivities was observed in study participants above the median age of 24.9 years (attributable proportion due to interaction = 0.45). This finding supports the hypothesis that HHV-6A and EBV infections interact in MS development. ANN NEUROL 2024;96:302-305.
(© 2024 The Author(s). Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.)
Databáze: MEDLINE
Externí odkaz: